Compound Profile: Tiniba
Tiniba 500 mg by Zydus Healthcare Ltd. is a pharmaceutical-grade tinidazole formulation designed for in-vitro laboratory research into antiprotozoal mechanisms and antimicrobial pathways. Tinidazole is a 5-nitroimidazole compound that serves as a valuable research tool for investigating anaerobic bacterial and protozoal resistance mechanisms in controlled laboratory environments. Researchers at Stroid UK Shop utilise this compound to examine cellular metabolic disruption pathways and DNA synthesis inhibition processes in microorganisms.
Laboratory Applications
This preparation enables researchers to investigate tinidazole’s mechanism of action through nitro group reduction under anaerobic conditions, leading to the formation of reactive metabolites that bind to DNA and proteins. Laboratory studies focus on examining the compound’s selectivity for anaerobic organisms and its effects on cellular respiration pathways. Research applications include studying drug resistance patterns in protozoal species and examining the pharmacokinetic properties of 5-nitroimidazole compounds. Scientists examining antimicrobial research can explore our uncategorized research compounds alongside complementary selective androgen receptor modulators and research peptides for comprehensive experimental protocols.
Technical Specifications
| Parameter | Value |
|---|---|
| Active Ingredient | Tinidazole |
| Strength | 500 mg per tablet |
| Manufacturer | Zydus Healthcare Ltd. |
| Molecular Formula | C₈H₁₃N₃O₄S |
| CAS Number | 19387-91-8 |
| Storage Conditions | Room temperature, dry environment |
| Intended Use | In-vitro research only |
Compliance Statement
Tiniba 500 mg Zydus Healthcare is intended exclusively for in-vitro laboratory research purposes. This pharmaceutical preparation is not intended for human consumption, clinical application, or therapeutic use. Researchers must ensure proper handling protocols within licensed laboratory facilities and maintain appropriate documentation for all experimental procedures. All research applications should comply with institutional guidelines and relevant regulatory frameworks governing antimicrobial resistance studies and pharmaceutical research.
